nodes	percent_of_prediction	percent_of_DWPC	metapath
Lenalidomide—TNFSF11—osteoporosis	0.537	1	CbGaD
Lenalidomide—PTGS2—Risedronate—osteoporosis	0.117	0.723	CbGbCtD
Lenalidomide—TNFSF11—jaw skeleton—osteoporosis	0.0215	0.352	CbGeAlD
Lenalidomide—ABCB1—Ethinyl Estradiol—osteoporosis	0.0188	0.116	CbGbCtD
Lenalidomide—TNFSF11—periosteum—osteoporosis	0.0162	0.266	CbGeAlD
Lenalidomide—ABCB1—Conjugated Estrogens—osteoporosis	0.0138	0.0855	CbGbCtD
Lenalidomide—TNFSF11—skull—osteoporosis	0.0133	0.219	CbGeAlD
Lenalidomide—ABCB1—Estradiol—osteoporosis	0.0121	0.075	CbGbCtD
Lenalidomide—TNFSF11—Osteoblast Signaling—IBSP—osteoporosis	0.0107	0.121	CbGpPWpGaD
Lenalidomide—TNFSF11—Osteoblast Signaling—PTH1R—osteoporosis	0.00966	0.109	CbGpPWpGaD
Lenalidomide—TNFSF11—Osteoclast Signaling—ACP5—osteoporosis	0.00536	0.0606	CbGpPWpGaD
Lenalidomide—TNFSF11—Osteoblast Signaling—PTH—osteoporosis	0.00507	0.0573	CbGpPWpGaD
Lenalidomide—TNFSF11—Osteoblast Signaling—TNFRSF11B—osteoporosis	0.00495	0.0558	CbGpPWpGaD
Lenalidomide—TNFSF11—Osteoclast Signaling—TNFRSF11B—osteoporosis	0.00444	0.0502	CbGpPWpGaD
Lenalidomide—TNFSF11—Osteoclast Signaling—CTSK—osteoporosis	0.00444	0.0502	CbGpPWpGaD
Lenalidomide—TNFSF11—Osteoblast Signaling—BGLAP—osteoporosis	0.00444	0.0501	CbGpPWpGaD
Lenalidomide—TNFSF11—Osteoblast Signaling—COL1A1—osteoporosis	0.00393	0.0444	CbGpPWpGaD
Lenalidomide—TNFSF11—RANKL/RANK Signaling Pathway—CALCR—osteoporosis	0.00323	0.0365	CbGpPWpGaD
Lenalidomide—CDH5—Cell junction organization—RSU1—osteoporosis	0.00239	0.027	CbGpPWpGaD
Lenalidomide—TNFSF11—Osteoclast Signaling—SPP1—osteoporosis	0.00229	0.0259	CbGpPWpGaD
Lenalidomide—PTGS2—periosteum—osteoporosis	0.00211	0.0346	CbGeAlD
Lenalidomide—TNFSF11—RANKL/RANK Signaling Pathway—ACP5—osteoporosis	0.002	0.0226	CbGpPWpGaD
Lenalidomide—TNFSF11—bone marrow—osteoporosis	0.00188	0.0309	CbGeAlD
Lenalidomide—TNFSF11—Differentiation Pathway—DKK1—osteoporosis	0.0018	0.0203	CbGpPWpGaD
Lenalidomide—TNFSF11—Differentiation Pathway—WNT1—osteoporosis	0.00174	0.0196	CbGpPWpGaD
Lenalidomide—CDH5—Cell-Cell communication—RSU1—osteoporosis	0.0017	0.0192	CbGpPWpGaD
Lenalidomide—CDH5—uterus—osteoporosis	0.00167	0.0274	CbGeAlD
Lenalidomide—TNFSF11—RANKL/RANK Signaling Pathway—CTSK—osteoporosis	0.00166	0.0187	CbGpPWpGaD
Lenalidomide—TNFSF11—RANKL/RANK Signaling Pathway—TNFRSF11B—osteoporosis	0.00166	0.0187	CbGpPWpGaD
Lenalidomide—TNFSF11—RANKL/RANK Signaling Pathway—NFATC1—osteoporosis	0.00163	0.0184	CbGpPWpGaD
Lenalidomide—Pomalidomide—TNF—osteoporosis	0.00148	0.608	CrCbGaD
Lenalidomide—CDH5—bone marrow—osteoporosis	0.00142	0.0232	CbGeAlD
Lenalidomide—CDH5—Signaling events mediated by VEGFR1 and VEGFR2—VCL—osteoporosis	0.00128	0.0144	CbGpPWpGaD
Lenalidomide—ABCB1—Drug Induction of Bile Acid Pathway—SLC51A—osteoporosis	0.00109	0.0124	CbGpPWpGaD
Lenalidomide—CRBN—uterus—osteoporosis	0.00106	0.0174	CbGeAlD
Lenalidomide—Thalidomide—TNF—osteoporosis	0.000954	0.392	CrCbGaD
Lenalidomide—CDH5—S1P2 pathway—IRS1—osteoporosis	0.000929	0.0105	CbGpPWpGaD
Lenalidomide—CRBN—bone marrow—osteoporosis	0.000899	0.0148	CbGeAlD
Lenalidomide—TNFSF11—IL6-mediated signaling events—IL6R—osteoporosis	0.000717	0.0081	CbGpPWpGaD
Lenalidomide—TNFSF11—Differentiation Pathway—IL6R—osteoporosis	0.000705	0.00796	CbGpPWpGaD
Lenalidomide—TNFSF11—Differentiation Pathway—IGF1—osteoporosis	0.000695	0.00785	CbGpPWpGaD
Lenalidomide—PTGS2—Synthesis of 15-eicosatetraenoic acid derivatives—GPX1—osteoporosis	0.000528	0.00597	CbGpPWpGaD
Lenalidomide—TNFSF11—IL6-mediated signaling events—MYC—osteoporosis	0.000425	0.0048	CbGpPWpGaD
Lenalidomide—TNFSF11—Differentiation Pathway—TGFB1—osteoporosis	0.000417	0.00471	CbGpPWpGaD
Lenalidomide—PTGS2—Prostaglandin Synthesis and Regulation—ANXA2—osteoporosis	0.00039	0.0044	CbGpPWpGaD
Lenalidomide—TNFSF11—IL6-mediated signaling events—IL6—osteoporosis	0.000319	0.00361	CbGpPWpGaD
Lenalidomide—TNFSF11—Differentiation Pathway—IL6—osteoporosis	0.000314	0.00355	CbGpPWpGaD
Lenalidomide—PTGS2—uterus—osteoporosis	0.000288	0.00473	CbGeAlD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—IL6R—osteoporosis	0.000281	0.00318	CbGpPWpGaD
Lenalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—NFATC1—osteoporosis	0.000278	0.00314	CbGpPWpGaD
Lenalidomide—CDH5—Signaling by VEGF—IL6R—osteoporosis	0.000266	0.003	CbGpPWpGaD
Lenalidomide—PTGS2—bone marrow—osteoporosis	0.000245	0.00402	CbGeAlD
Lenalidomide—PTGS2—Selenium Micronutrient Network—PRDX3—osteoporosis	0.000238	0.00269	CbGpPWpGaD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—PKM—osteoporosis	0.000224	0.00253	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—NFATC1—osteoporosis	0.00018	0.00203	CbGpPWpGaD
Lenalidomide—ABCB1—uterus—osteoporosis	0.000178	0.00293	CbGeAlD
Lenalidomide—ABCB1—Drug Induction of Bile Acid Pathway—VDR—osteoporosis	0.000175	0.00197	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—TUBA1B—osteoporosis	0.000156	0.00177	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—SOST—osteoporosis	0.000156	0.00176	CbGpPWpGaD
Lenalidomide—ABCB1—bone marrow—osteoporosis	0.000151	0.00249	CbGeAlD
Lenalidomide—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—ACP5—osteoporosis	0.000141	0.0016	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PTH1R—osteoporosis	0.000141	0.00159	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CALCR—osteoporosis	0.000141	0.00159	CbGpPWpGaD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—IL6—osteoporosis	0.000125	0.00142	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—COL1A2—osteoporosis	0.000125	0.00141	CbGpPWpGaD
Lenalidomide—CDH5—Signaling by VEGF—IL6—osteoporosis	0.000118	0.00134	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—WNT1—osteoporosis	0.000113	0.00128	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—MGLL—osteoporosis	0.000112	0.00126	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—LRP5—osteoporosis	0.000109	0.00123	CbGpPWpGaD
Lenalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—ESR1—osteoporosis	0.000106	0.00119	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—LRP6—osteoporosis	0.000104	0.00118	CbGpPWpGaD
Lenalidomide—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—osteoporosis	0.0001	0.00113	CbGpPWpGaD
Lenalidomide—PTGS2—Arachidonic acid metabolism—GPX1—osteoporosis	9.69e-05	0.00109	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—TLN1—osteoporosis	8.81e-05	0.000995	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—ESR1—osteoporosis	8.5e-05	0.00096	CbGpPWpGaD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—ENO1—osteoporosis	8.45e-05	0.000954	CbGpPWpGaD
Lenalidomide—PTGS2—Overview of nanoparticle effects—TNF—osteoporosis	8.35e-05	0.000943	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—P4HB—osteoporosis	7.6e-05	0.000858	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PTH—osteoporosis	7.39e-05	0.000835	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—RAP1A—osteoporosis	7.27e-05	0.00082	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CNR2—osteoporosis	7.2e-05	0.000814	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—NFATC1—osteoporosis	7.09e-05	0.0008	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—DKK1—osteoporosis	7.03e-05	0.000794	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—WNT1—osteoporosis	6.77e-05	0.000765	CbGpPWpGaD
Lenalidomide—PTGS2—Overview of nanoparticle effects—IL6—osteoporosis	6.74e-05	0.000761	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—FGA—osteoporosis	6.59e-05	0.000744	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—SOD2—osteoporosis	6.46e-05	0.00073	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—RAP1A—osteoporosis	6.3e-05	0.000712	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—GPX1—osteoporosis	6.17e-05	0.000696	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—BMP2—osteoporosis	6.13e-05	0.000692	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PTHLH—osteoporosis	6.13e-05	0.000692	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—FGB—osteoporosis	5.99e-05	0.000677	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PSMA2—osteoporosis	5.79e-05	0.000654	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PSMA5—osteoporosis	5.79e-05	0.000654	CbGpPWpGaD
Lenalidomide—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—MTHFR—osteoporosis	5.74e-05	0.000648	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—MTHFR—osteoporosis	5.69e-05	0.000643	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—FDPS—osteoporosis	5.64e-05	0.000637	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CALCA—osteoporosis	5.39e-05	0.000609	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—GPD2—osteoporosis	5.34e-05	0.000604	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—KL—osteoporosis	4.9e-05	0.000553	CbGpPWpGaD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—LEP—osteoporosis	4.73e-05	0.000534	CbGpPWpGaD
Lenalidomide—Dry mouth—Zoledronate—osteoporosis	4.5e-05	0.0003	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	4.5e-05	0.000299	CcSEcCtD
Lenalidomide—Fatigue—Ethinyl Estradiol—osteoporosis	4.49e-05	0.000299	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—ESR2—osteoporosis	4.49e-05	0.000507	CbGpPWpGaD
Lenalidomide—Pruritus—Alendronate—osteoporosis	4.48e-05	0.000298	CcSEcCtD
Lenalidomide—Dyspepsia—Risedronate—osteoporosis	4.47e-05	0.000298	CcSEcCtD
Lenalidomide—Eye disorder—Estradiol—osteoporosis	4.47e-05	0.000298	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—RAP1A—osteoporosis	4.47e-05	0.000505	CbGpPWpGaD
Lenalidomide—Tinnitus—Estradiol—osteoporosis	4.46e-05	0.000297	CcSEcCtD
Lenalidomide—Constipation—Ethinyl Estradiol—osteoporosis	4.46e-05	0.000297	CcSEcCtD
Lenalidomide—Confusional state—Zoledronate—osteoporosis	4.45e-05	0.000296	CcSEcCtD
Lenalidomide—Hypersensitivity—Calcitriol—osteoporosis	4.45e-05	0.000296	CcSEcCtD
Lenalidomide—Cardiac disorder—Estradiol—osteoporosis	4.44e-05	0.000296	CcSEcCtD
Lenalidomide—Flushing—Estradiol—osteoporosis	4.44e-05	0.000296	CcSEcCtD
Lenalidomide—Myalgia—Conjugated Estrogens—osteoporosis	4.43e-05	0.000295	CcSEcCtD
Lenalidomide—Arthralgia—Conjugated Estrogens—osteoporosis	4.43e-05	0.000295	CcSEcCtD
Lenalidomide—Chest pain—Conjugated Estrogens—osteoporosis	4.43e-05	0.000295	CcSEcCtD
Lenalidomide—Asthenia—Ibandronate—osteoporosis	4.43e-05	0.000294	CcSEcCtD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—MYC—osteoporosis	4.42e-05	0.000499	CbGpPWpGaD
Lenalidomide—Anxiety—Conjugated Estrogens—osteoporosis	4.42e-05	0.000294	CcSEcCtD
Lenalidomide—Nausea—Etidronic acid—osteoporosis	4.42e-05	0.000294	CcSEcCtD
Lenalidomide—Oedema—Zoledronate—osteoporosis	4.41e-05	0.000294	CcSEcCtD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	4.4e-05	0.000293	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Pamidronate—osteoporosis	4.4e-05	0.000293	CcSEcCtD
Lenalidomide—Diarrhoea—Estropipate—osteoporosis	4.4e-05	0.000293	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Risedronate—osteoporosis	4.39e-05	0.000292	CcSEcCtD
Lenalidomide—Infection—Zoledronate—osteoporosis	4.38e-05	0.000292	CcSEcCtD
Lenalidomide—Fatigue—Risedronate—osteoporosis	4.38e-05	0.000292	CcSEcCtD
Lenalidomide—Insomnia—Pamidronate—osteoporosis	4.37e-05	0.000291	CcSEcCtD
Lenalidomide—Pruritus—Ibandronate—osteoporosis	4.36e-05	0.00029	CcSEcCtD
Lenalidomide—Constipation—Risedronate—osteoporosis	4.35e-05	0.000289	CcSEcCtD
Lenalidomide—Pain—Risedronate—osteoporosis	4.35e-05	0.000289	CcSEcCtD
Lenalidomide—Angiopathy—Estradiol—osteoporosis	4.34e-05	0.000289	CcSEcCtD
Lenalidomide—Shock—Zoledronate—osteoporosis	4.34e-05	0.000289	CcSEcCtD
Lenalidomide—Paraesthesia—Pamidronate—osteoporosis	4.34e-05	0.000289	CcSEcCtD
Lenalidomide—Diarrhoea—Alendronate—osteoporosis	4.33e-05	0.000288	CcSEcCtD
Lenalidomide—Asthenia—Calcitriol—osteoporosis	4.33e-05	0.000288	CcSEcCtD
Lenalidomide—Nervous system disorder—Zoledronate—osteoporosis	4.33e-05	0.000288	CcSEcCtD
Lenalidomide—Immune system disorder—Estradiol—osteoporosis	4.32e-05	0.000288	CcSEcCtD
Lenalidomide—Thrombocytopenia—Zoledronate—osteoporosis	4.32e-05	0.000288	CcSEcCtD
Lenalidomide—Mediastinal disorder—Estradiol—osteoporosis	4.31e-05	0.000287	CcSEcCtD
Lenalidomide—Dyspnoea—Pamidronate—osteoporosis	4.31e-05	0.000287	CcSEcCtD
Lenalidomide—Tachycardia—Zoledronate—osteoporosis	4.31e-05	0.000287	CcSEcCtD
Lenalidomide—Feeling abnormal—Ethinyl Estradiol—osteoporosis	4.3e-05	0.000286	CcSEcCtD
Lenalidomide—Chills—Estradiol—osteoporosis	4.3e-05	0.000286	CcSEcCtD
Lenalidomide—Somnolence—Pamidronate—osteoporosis	4.3e-05	0.000286	CcSEcCtD
Lenalidomide—Skin disorder—Zoledronate—osteoporosis	4.29e-05	0.000285	CcSEcCtD
Lenalidomide—Pruritus—Calcitriol—osteoporosis	4.27e-05	0.000284	CcSEcCtD
Lenalidomide—Hyperhidrosis—Zoledronate—osteoporosis	4.27e-05	0.000284	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Ethinyl Estradiol—osteoporosis	4.26e-05	0.000284	CcSEcCtD
Lenalidomide—Diarrhoea—Raloxifene—osteoporosis	4.26e-05	0.000284	CcSEcCtD
Lenalidomide—Dyspepsia—Pamidronate—osteoporosis	4.25e-05	0.000283	CcSEcCtD
Lenalidomide—Dizziness—Estropipate—osteoporosis	4.25e-05	0.000283	CcSEcCtD
Lenalidomide—Oedema—Conjugated Estrogens—osteoporosis	4.25e-05	0.000283	CcSEcCtD
Lenalidomide—Alopecia—Estradiol—osteoporosis	4.23e-05	0.000281	CcSEcCtD
Lenalidomide—Infection—Conjugated Estrogens—osteoporosis	4.22e-05	0.000281	CcSEcCtD
Lenalidomide—Diarrhoea—Ibandronate—osteoporosis	4.22e-05	0.000281	CcSEcCtD
Lenalidomide—Anorexia—Zoledronate—osteoporosis	4.21e-05	0.00028	CcSEcCtD
Lenalidomide—Decreased appetite—Pamidronate—osteoporosis	4.2e-05	0.000279	CcSEcCtD
Lenalidomide—Mental disorder—Estradiol—osteoporosis	4.19e-05	0.000279	CcSEcCtD
Lenalidomide—Dizziness—Alendronate—osteoporosis	4.19e-05	0.000279	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—LEP—osteoporosis	4.19e-05	0.000473	CbGpPWpGaD
Lenalidomide—Shock—Conjugated Estrogens—osteoporosis	4.18e-05	0.000278	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Pamidronate—osteoporosis	4.17e-05	0.000278	CcSEcCtD
Lenalidomide—Nervous system disorder—Conjugated Estrogens—osteoporosis	4.17e-05	0.000277	CcSEcCtD
Lenalidomide—Malnutrition—Estradiol—osteoporosis	4.17e-05	0.000277	CcSEcCtD
Lenalidomide—Erythema—Estradiol—osteoporosis	4.17e-05	0.000277	CcSEcCtD
Lenalidomide—Fatigue—Pamidronate—osteoporosis	4.17e-05	0.000277	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Risedronate—osteoporosis	4.16e-05	0.000277	CcSEcCtD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—OXCT1—osteoporosis	4.16e-05	0.000469	CbGpPWpGaD
Lenalidomide—Tachycardia—Conjugated Estrogens—osteoporosis	4.15e-05	0.000276	CcSEcCtD
Lenalidomide—Urticaria—Ethinyl Estradiol—osteoporosis	4.14e-05	0.000276	CcSEcCtD
Lenalidomide—Pain—Pamidronate—osteoporosis	4.13e-05	0.000275	CcSEcCtD
Lenalidomide—Constipation—Pamidronate—osteoporosis	4.13e-05	0.000275	CcSEcCtD
Lenalidomide—Diarrhoea—Calcitriol—osteoporosis	4.13e-05	0.000275	CcSEcCtD
Lenalidomide—Skin disorder—Conjugated Estrogens—osteoporosis	4.13e-05	0.000275	CcSEcCtD
Lenalidomide—Hypotension—Zoledronate—osteoporosis	4.12e-05	0.000274	CcSEcCtD
Lenalidomide—Body temperature increased—Ethinyl Estradiol—osteoporosis	4.12e-05	0.000274	CcSEcCtD
Lenalidomide—Abdominal pain—Ethinyl Estradiol—osteoporosis	4.12e-05	0.000274	CcSEcCtD
Lenalidomide—Dizziness—Raloxifene—osteoporosis	4.12e-05	0.000274	CcSEcCtD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—TNF—osteoporosis	4.12e-05	0.000465	CbGpPWpGaD
Lenalidomide—Hyperhidrosis—Conjugated Estrogens—osteoporosis	4.11e-05	0.000273	CcSEcCtD
Lenalidomide—Flatulence—Estradiol—osteoporosis	4.11e-05	0.000273	CcSEcCtD
Lenalidomide—Tension—Estradiol—osteoporosis	4.09e-05	0.000272	CcSEcCtD
Lenalidomide—Vomiting—Estropipate—osteoporosis	4.09e-05	0.000272	CcSEcCtD
Lenalidomide—Dysgeusia—Estradiol—osteoporosis	4.08e-05	0.000272	CcSEcCtD
Lenalidomide—Dizziness—Ibandronate—osteoporosis	4.08e-05	0.000271	CcSEcCtD
Lenalidomide—Rash—Estropipate—osteoporosis	4.06e-05	0.00027	CcSEcCtD
Lenalidomide—Dermatitis—Estropipate—osteoporosis	4.05e-05	0.00027	CcSEcCtD
Lenalidomide—Anorexia—Conjugated Estrogens—osteoporosis	4.05e-05	0.00027	CcSEcCtD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—MGLL—osteoporosis	4.05e-05	0.000457	CbGpPWpGaD
Lenalidomide—Nervousness—Estradiol—osteoporosis	4.05e-05	0.000269	CcSEcCtD
Lenalidomide—Urticaria—Risedronate—osteoporosis	4.04e-05	0.000269	CcSEcCtD
Lenalidomide—Back pain—Estradiol—osteoporosis	4.03e-05	0.000268	CcSEcCtD
Lenalidomide—Headache—Estropipate—osteoporosis	4.03e-05	0.000268	CcSEcCtD
Lenalidomide—Vomiting—Alendronate—osteoporosis	4.03e-05	0.000268	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Zoledronate—osteoporosis	4.02e-05	0.000268	CcSEcCtD
Lenalidomide—Body temperature increased—Risedronate—osteoporosis	4.02e-05	0.000267	CcSEcCtD
Lenalidomide—Abdominal pain—Risedronate—osteoporosis	4.02e-05	0.000267	CcSEcCtD
Lenalidomide—Muscle spasms—Estradiol—osteoporosis	4.01e-05	0.000267	CcSEcCtD
Lenalidomide—Rash—Alendronate—osteoporosis	3.99e-05	0.000266	CcSEcCtD
Lenalidomide—Insomnia—Zoledronate—osteoporosis	3.99e-05	0.000266	CcSEcCtD
Lenalidomide—Dermatitis—Alendronate—osteoporosis	3.99e-05	0.000266	CcSEcCtD
Lenalidomide—Feeling abnormal—Pamidronate—osteoporosis	3.98e-05	0.000265	CcSEcCtD
Lenalidomide—Hypotension—Conjugated Estrogens—osteoporosis	3.97e-05	0.000264	CcSEcCtD
Lenalidomide—Headache—Alendronate—osteoporosis	3.97e-05	0.000264	CcSEcCtD
Lenalidomide—Paraesthesia—Zoledronate—osteoporosis	3.96e-05	0.000264	CcSEcCtD
Lenalidomide—Vomiting—Raloxifene—osteoporosis	3.96e-05	0.000264	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Pamidronate—osteoporosis	3.95e-05	0.000263	CcSEcCtD
Lenalidomide—Dyspnoea—Zoledronate—osteoporosis	3.93e-05	0.000262	CcSEcCtD
Lenalidomide—Rash—Raloxifene—osteoporosis	3.93e-05	0.000261	CcSEcCtD
Lenalidomide—Dermatitis—Raloxifene—osteoporosis	3.92e-05	0.000261	CcSEcCtD
Lenalidomide—Somnolence—Zoledronate—osteoporosis	3.92e-05	0.000261	CcSEcCtD
Lenalidomide—Vomiting—Ibandronate—osteoporosis	3.92e-05	0.000261	CcSEcCtD
Lenalidomide—Tremor—Estradiol—osteoporosis	3.9e-05	0.00026	CcSEcCtD
Lenalidomide—Headache—Raloxifene—osteoporosis	3.9e-05	0.00026	CcSEcCtD
Lenalidomide—Rash—Ibandronate—osteoporosis	3.89e-05	0.000259	CcSEcCtD
Lenalidomide—Dermatitis—Ibandronate—osteoporosis	3.89e-05	0.000259	CcSEcCtD
Lenalidomide—Dyspepsia—Zoledronate—osteoporosis	3.89e-05	0.000258	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Conjugated Estrogens—osteoporosis	3.87e-05	0.000258	CcSEcCtD
Lenalidomide—Ill-defined disorder—Estradiol—osteoporosis	3.87e-05	0.000257	CcSEcCtD
Lenalidomide—Headache—Ibandronate—osteoporosis	3.86e-05	0.000257	CcSEcCtD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—osteoporosis	3.85e-05	0.000435	CbGpPWpGaD
Lenalidomide—Insomnia—Conjugated Estrogens—osteoporosis	3.84e-05	0.000256	CcSEcCtD
Lenalidomide—Hypersensitivity—Ethinyl Estradiol—osteoporosis	3.84e-05	0.000256	CcSEcCtD
Lenalidomide—Vomiting—Calcitriol—osteoporosis	3.84e-05	0.000255	CcSEcCtD
Lenalidomide—Decreased appetite—Zoledronate—osteoporosis	3.84e-05	0.000255	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—ADCY5—osteoporosis	3.84e-05	0.000433	CbGpPWpGaD
Lenalidomide—Agitation—Estradiol—osteoporosis	3.83e-05	0.000255	CcSEcCtD
Lenalidomide—Nausea—Estropipate—osteoporosis	3.82e-05	0.000254	CcSEcCtD
Lenalidomide—Abdominal pain—Pamidronate—osteoporosis	3.82e-05	0.000254	CcSEcCtD
Lenalidomide—Body temperature increased—Pamidronate—osteoporosis	3.82e-05	0.000254	CcSEcCtD
Lenalidomide—Paraesthesia—Conjugated Estrogens—osteoporosis	3.82e-05	0.000254	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Zoledronate—osteoporosis	3.81e-05	0.000254	CcSEcCtD
Lenalidomide—Angioedema—Estradiol—osteoporosis	3.81e-05	0.000253	CcSEcCtD
Lenalidomide—Rash—Calcitriol—osteoporosis	3.81e-05	0.000253	CcSEcCtD
Lenalidomide—Fatigue—Zoledronate—osteoporosis	3.81e-05	0.000253	CcSEcCtD
Lenalidomide—Dermatitis—Calcitriol—osteoporosis	3.8e-05	0.000253	CcSEcCtD
Lenalidomide—Dyspnoea—Conjugated Estrogens—osteoporosis	3.79e-05	0.000252	CcSEcCtD
Lenalidomide—Headache—Calcitriol—osteoporosis	3.78e-05	0.000252	CcSEcCtD
Lenalidomide—Somnolence—Conjugated Estrogens—osteoporosis	3.78e-05	0.000251	CcSEcCtD
Lenalidomide—Constipation—Zoledronate—osteoporosis	3.77e-05	0.000251	CcSEcCtD
Lenalidomide—Pain—Zoledronate—osteoporosis	3.77e-05	0.000251	CcSEcCtD
Lenalidomide—Nausea—Alendronate—osteoporosis	3.76e-05	0.00025	CcSEcCtD
Lenalidomide—Malaise—Estradiol—osteoporosis	3.76e-05	0.00025	CcSEcCtD
Lenalidomide—Hypersensitivity—Risedronate—osteoporosis	3.74e-05	0.000249	CcSEcCtD
Lenalidomide—Vertigo—Estradiol—osteoporosis	3.74e-05	0.000249	CcSEcCtD
Lenalidomide—Dyspepsia—Conjugated Estrogens—osteoporosis	3.74e-05	0.000249	CcSEcCtD
Lenalidomide—Asthenia—Ethinyl Estradiol—osteoporosis	3.74e-05	0.000249	CcSEcCtD
Lenalidomide—Syncope—Estradiol—osteoporosis	3.74e-05	0.000249	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—SPP1—osteoporosis	3.71e-05	0.000419	CbGpPWpGaD
Lenalidomide—Nausea—Raloxifene—osteoporosis	3.7e-05	0.000246	CcSEcCtD
Lenalidomide—Decreased appetite—Conjugated Estrogens—osteoporosis	3.69e-05	0.000246	CcSEcCtD
Lenalidomide—Pruritus—Ethinyl Estradiol—osteoporosis	3.69e-05	0.000245	CcSEcCtD
Lenalidomide—Palpitations—Estradiol—osteoporosis	3.68e-05	0.000245	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	3.67e-05	0.000244	CcSEcCtD
Lenalidomide—Fatigue—Conjugated Estrogens—osteoporosis	3.66e-05	0.000244	CcSEcCtD
Lenalidomide—Nausea—Ibandronate—osteoporosis	3.66e-05	0.000244	CcSEcCtD
Lenalidomide—Loss of consciousness—Estradiol—osteoporosis	3.66e-05	0.000244	CcSEcCtD
Lenalidomide—Asthenia—Risedronate—osteoporosis	3.65e-05	0.000243	CcSEcCtD
Lenalidomide—Feeling abnormal—Zoledronate—osteoporosis	3.64e-05	0.000242	CcSEcCtD
Lenalidomide—Cough—Estradiol—osteoporosis	3.64e-05	0.000242	CcSEcCtD
Lenalidomide—Pain—Conjugated Estrogens—osteoporosis	3.63e-05	0.000242	CcSEcCtD
Lenalidomide—Constipation—Conjugated Estrogens—osteoporosis	3.63e-05	0.000242	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Zoledronate—osteoporosis	3.61e-05	0.00024	CcSEcCtD
Lenalidomide—Hypertension—Estradiol—osteoporosis	3.6e-05	0.000239	CcSEcCtD
Lenalidomide—Pruritus—Risedronate—osteoporosis	3.6e-05	0.000239	CcSEcCtD
Lenalidomide—Nausea—Calcitriol—osteoporosis	3.59e-05	0.000239	CcSEcCtD
Lenalidomide—Diarrhoea—Ethinyl Estradiol—osteoporosis	3.57e-05	0.000237	CcSEcCtD
Lenalidomide—Hypersensitivity—Pamidronate—osteoporosis	3.56e-05	0.000237	CcSEcCtD
Lenalidomide—Arthralgia—Estradiol—osteoporosis	3.55e-05	0.000236	CcSEcCtD
Lenalidomide—Chest pain—Estradiol—osteoporosis	3.55e-05	0.000236	CcSEcCtD
Lenalidomide—Myalgia—Estradiol—osteoporosis	3.55e-05	0.000236	CcSEcCtD
Lenalidomide—Anxiety—Estradiol—osteoporosis	3.54e-05	0.000235	CcSEcCtD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	3.52e-05	0.000234	CcSEcCtD
Lenalidomide—Urticaria—Zoledronate—osteoporosis	3.51e-05	0.000233	CcSEcCtD
Lenalidomide—Discomfort—Estradiol—osteoporosis	3.51e-05	0.000233	CcSEcCtD
Lenalidomide—Abdominal pain—Zoledronate—osteoporosis	3.49e-05	0.000232	CcSEcCtD
Lenalidomide—Body temperature increased—Zoledronate—osteoporosis	3.49e-05	0.000232	CcSEcCtD
Lenalidomide—Diarrhoea—Risedronate—osteoporosis	3.48e-05	0.000231	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Conjugated Estrogens—osteoporosis	3.48e-05	0.000231	CcSEcCtD
Lenalidomide—Dry mouth—Estradiol—osteoporosis	3.47e-05	0.000231	CcSEcCtD
Lenalidomide—Asthenia—Pamidronate—osteoporosis	3.47e-05	0.000231	CcSEcCtD
Lenalidomide—Dizziness—Ethinyl Estradiol—osteoporosis	3.45e-05	0.000229	CcSEcCtD
Lenalidomide—Confusional state—Estradiol—osteoporosis	3.43e-05	0.000228	CcSEcCtD
Lenalidomide—Pruritus—Pamidronate—osteoporosis	3.42e-05	0.000227	CcSEcCtD
Lenalidomide—Oedema—Estradiol—osteoporosis	3.4e-05	0.000226	CcSEcCtD
Lenalidomide—Infection—Estradiol—osteoporosis	3.38e-05	0.000225	CcSEcCtD
Lenalidomide—PTGS2—Selenium Micronutrient Network—IL1B—osteoporosis	3.38e-05	0.000381	CbGpPWpGaD
Lenalidomide—Urticaria—Conjugated Estrogens—osteoporosis	3.38e-05	0.000225	CcSEcCtD
Lenalidomide—Dizziness—Risedronate—osteoporosis	3.36e-05	0.000224	CcSEcCtD
Lenalidomide—Body temperature increased—Conjugated Estrogens—osteoporosis	3.36e-05	0.000224	CcSEcCtD
Lenalidomide—Abdominal pain—Conjugated Estrogens—osteoporosis	3.36e-05	0.000224	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—IRS2—osteoporosis	3.36e-05	0.000379	CbGpPWpGaD
Lenalidomide—Shock—Estradiol—osteoporosis	3.35e-05	0.000223	CcSEcCtD
Lenalidomide—Nervous system disorder—Estradiol—osteoporosis	3.34e-05	0.000222	CcSEcCtD
Lenalidomide—Tachycardia—Estradiol—osteoporosis	3.32e-05	0.000221	CcSEcCtD
Lenalidomide—Vomiting—Ethinyl Estradiol—osteoporosis	3.31e-05	0.000221	CcSEcCtD
Lenalidomide—Diarrhoea—Pamidronate—osteoporosis	3.31e-05	0.00022	CcSEcCtD
Lenalidomide—Skin disorder—Estradiol—osteoporosis	3.3e-05	0.00022	CcSEcCtD
Lenalidomide—Hyperhidrosis—Estradiol—osteoporosis	3.29e-05	0.000219	CcSEcCtD
Lenalidomide—Rash—Ethinyl Estradiol—osteoporosis	3.29e-05	0.000219	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—LEP—osteoporosis	3.28e-05	0.000371	CbGpPWpGaD
Lenalidomide—Dermatitis—Ethinyl Estradiol—osteoporosis	3.28e-05	0.000219	CcSEcCtD
Lenalidomide—Headache—Ethinyl Estradiol—osteoporosis	3.27e-05	0.000217	CcSEcCtD
Lenalidomide—Hypersensitivity—Zoledronate—osteoporosis	3.25e-05	0.000216	CcSEcCtD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—CYP27A1—osteoporosis	3.24e-05	0.000366	CbGpPWpGaD
Lenalidomide—Vomiting—Risedronate—osteoporosis	3.23e-05	0.000215	CcSEcCtD
Lenalidomide—Rash—Risedronate—osteoporosis	3.2e-05	0.000213	CcSEcCtD
Lenalidomide—Dermatitis—Risedronate—osteoporosis	3.2e-05	0.000213	CcSEcCtD
Lenalidomide—Dizziness—Pamidronate—osteoporosis	3.2e-05	0.000213	CcSEcCtD
Lenalidomide—Headache—Risedronate—osteoporosis	3.18e-05	0.000212	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—ESR2—osteoporosis	3.18e-05	0.000359	CbGpPWpGaD
Lenalidomide—Asthenia—Zoledronate—osteoporosis	3.17e-05	0.000211	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—ESR1—osteoporosis	3.14e-05	0.000354	CbGpPWpGaD
Lenalidomide—Hypersensitivity—Conjugated Estrogens—osteoporosis	3.13e-05	0.000208	CcSEcCtD
Lenalidomide—Pruritus—Zoledronate—osteoporosis	3.12e-05	0.000208	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Estradiol—osteoporosis	3.1e-05	0.000206	CcSEcCtD
Lenalidomide—Nausea—Ethinyl Estradiol—osteoporosis	3.1e-05	0.000206	CcSEcCtD
Lenalidomide—Insomnia—Estradiol—osteoporosis	3.08e-05	0.000205	CcSEcCtD
Lenalidomide—Vomiting—Pamidronate—osteoporosis	3.07e-05	0.000204	CcSEcCtD
Lenalidomide—Paraesthesia—Estradiol—osteoporosis	3.05e-05	0.000203	CcSEcCtD
Lenalidomide—Asthenia—Conjugated Estrogens—osteoporosis	3.05e-05	0.000203	CcSEcCtD
Lenalidomide—Rash—Pamidronate—osteoporosis	3.05e-05	0.000203	CcSEcCtD
Lenalidomide—Dermatitis—Pamidronate—osteoporosis	3.04e-05	0.000203	CcSEcCtD
Lenalidomide—Dyspnoea—Estradiol—osteoporosis	3.03e-05	0.000202	CcSEcCtD
Lenalidomide—Headache—Pamidronate—osteoporosis	3.03e-05	0.000201	CcSEcCtD
Lenalidomide—Somnolence—Estradiol—osteoporosis	3.02e-05	0.000201	CcSEcCtD
Lenalidomide—Diarrhoea—Zoledronate—osteoporosis	3.02e-05	0.000201	CcSEcCtD
Lenalidomide—Nausea—Risedronate—osteoporosis	3.02e-05	0.000201	CcSEcCtD
Lenalidomide—Pruritus—Conjugated Estrogens—osteoporosis	3.01e-05	0.0002	CcSEcCtD
Lenalidomide—PTGS2—Disease—PKM—osteoporosis	3e-05	0.000339	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—SOST—osteoporosis	3e-05	0.000339	CbGpPWpGaD
Lenalidomide—Dyspepsia—Estradiol—osteoporosis	2.99e-05	0.000199	CcSEcCtD
Lenalidomide—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—osteoporosis	2.98e-05	0.000336	CbGpPWpGaD
Lenalidomide—Decreased appetite—Estradiol—osteoporosis	2.96e-05	0.000197	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Estradiol—osteoporosis	2.94e-05	0.000195	CcSEcCtD
Lenalidomide—Fatigue—Estradiol—osteoporosis	2.93e-05	0.000195	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—IRS1—osteoporosis	2.93e-05	0.000331	CbGpPWpGaD
Lenalidomide—Dizziness—Zoledronate—osteoporosis	2.92e-05	0.000194	CcSEcCtD
Lenalidomide—Constipation—Estradiol—osteoporosis	2.91e-05	0.000194	CcSEcCtD
Lenalidomide—Pain—Estradiol—osteoporosis	2.91e-05	0.000194	CcSEcCtD
Lenalidomide—Diarrhoea—Conjugated Estrogens—osteoporosis	2.91e-05	0.000193	CcSEcCtD
Lenalidomide—Nausea—Pamidronate—osteoporosis	2.87e-05	0.000191	CcSEcCtD
Lenalidomide—PTGS2—Disease—PGLS—osteoporosis	2.84e-05	0.000321	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—ANTXR2—osteoporosis	2.84e-05	0.000321	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—POMC—osteoporosis	2.82e-05	0.000319	CbGpPWpGaD
Lenalidomide—Dizziness—Conjugated Estrogens—osteoporosis	2.81e-05	0.000187	CcSEcCtD
Lenalidomide—Vomiting—Zoledronate—osteoporosis	2.81e-05	0.000187	CcSEcCtD
Lenalidomide—Feeling abnormal—Estradiol—osteoporosis	2.8e-05	0.000186	CcSEcCtD
Lenalidomide—Rash—Zoledronate—osteoporosis	2.78e-05	0.000185	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Estradiol—osteoporosis	2.78e-05	0.000185	CcSEcCtD
Lenalidomide—Dermatitis—Zoledronate—osteoporosis	2.78e-05	0.000185	CcSEcCtD
Lenalidomide—Headache—Zoledronate—osteoporosis	2.76e-05	0.000184	CcSEcCtD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	2.75e-05	0.000311	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—IL6R—osteoporosis	2.75e-05	0.000311	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—MYC—osteoporosis	2.73e-05	0.000308	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—ESR1—osteoporosis	2.72e-05	0.000307	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—IGF1—osteoporosis	2.71e-05	0.000307	CbGpPWpGaD
Lenalidomide—Vomiting—Conjugated Estrogens—osteoporosis	2.7e-05	0.00018	CcSEcCtD
Lenalidomide—Urticaria—Estradiol—osteoporosis	2.7e-05	0.00018	CcSEcCtD
Lenalidomide—Body temperature increased—Estradiol—osteoporosis	2.69e-05	0.000179	CcSEcCtD
Lenalidomide—Abdominal pain—Estradiol—osteoporosis	2.69e-05	0.000179	CcSEcCtD
Lenalidomide—Rash—Conjugated Estrogens—osteoporosis	2.68e-05	0.000178	CcSEcCtD
Lenalidomide—Dermatitis—Conjugated Estrogens—osteoporosis	2.68e-05	0.000178	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—IL1B—osteoporosis	2.67e-05	0.000302	CbGpPWpGaD
Lenalidomide—Headache—Conjugated Estrogens—osteoporosis	2.66e-05	0.000177	CcSEcCtD
Lenalidomide—Nausea—Zoledronate—osteoporosis	2.62e-05	0.000174	CcSEcCtD
Lenalidomide—ABCB1—Allograft Rejection—IL1B—osteoporosis	2.61e-05	0.000295	CbGpPWpGaD
Lenalidomide—Nausea—Conjugated Estrogens—osteoporosis	2.52e-05	0.000168	CcSEcCtD
Lenalidomide—PTGS2—Metabolism—FDPS—osteoporosis	2.51e-05	0.000284	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PKM—osteoporosis	2.51e-05	0.000284	CbGpPWpGaD
Lenalidomide—Hypersensitivity—Estradiol—osteoporosis	2.51e-05	0.000167	CcSEcCtD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—ANXA2—osteoporosis	2.5e-05	0.000282	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—TNF—osteoporosis	2.45e-05	0.000277	CbGpPWpGaD
Lenalidomide—Asthenia—Estradiol—osteoporosis	2.44e-05	0.000162	CcSEcCtD
Lenalidomide—PTGS2—Disease—GSN—osteoporosis	2.42e-05	0.000273	CbGpPWpGaD
Lenalidomide—Pruritus—Estradiol—osteoporosis	2.41e-05	0.00016	CcSEcCtD
Lenalidomide—PTGS2—Metabolism—PGLS—osteoporosis	2.38e-05	0.000269	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—GPD2—osteoporosis	2.38e-05	0.000269	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—IGF1—osteoporosis	2.35e-05	0.000266	CbGpPWpGaD
Lenalidomide—Diarrhoea—Estradiol—osteoporosis	2.33e-05	0.000155	CcSEcCtD
Lenalidomide—Dizziness—Estradiol—osteoporosis	2.25e-05	0.00015	CcSEcCtD
Lenalidomide—PTGS2—Metabolism—ATIC—osteoporosis	2.18e-05	0.000246	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PNP—osteoporosis	2.18e-05	0.000246	CbGpPWpGaD
Lenalidomide—Vomiting—Estradiol—osteoporosis	2.16e-05	0.000144	CcSEcCtD
Lenalidomide—Rash—Estradiol—osteoporosis	2.14e-05	0.000143	CcSEcCtD
Lenalidomide—Dermatitis—Estradiol—osteoporosis	2.14e-05	0.000143	CcSEcCtD
Lenalidomide—Headache—Estradiol—osteoporosis	2.13e-05	0.000142	CcSEcCtD
Lenalidomide—PTGS2—Disease—LRP5—osteoporosis	2.1e-05	0.000237	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—MYC—osteoporosis	2.08e-05	0.000235	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—TGFB1—osteoporosis	2.08e-05	0.000234	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—TGFB1—osteoporosis	2.03e-05	0.000229	CbGpPWpGaD
Lenalidomide—Nausea—Estradiol—osteoporosis	2.02e-05	0.000134	CcSEcCtD
Lenalidomide—PTGS2—Disease—LRP6—osteoporosis	2.01e-05	0.000227	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—IL6—osteoporosis	1.98e-05	0.000223	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—TNF—osteoporosis	1.94e-05	0.000219	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—RPL24—osteoporosis	1.93e-05	0.000218	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—LTF—osteoporosis	1.93e-05	0.000218	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—osteoporosis	1.93e-05	0.000218	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—TNF—osteoporosis	1.89e-05	0.000214	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CA2—osteoporosis	1.85e-05	0.000209	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—OXCT1—osteoporosis	1.85e-05	0.000209	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—MGLL—osteoporosis	1.8e-05	0.000204	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—FDPS—osteoporosis	1.78e-05	0.000201	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PKM—osteoporosis	1.78e-05	0.000201	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	1.7e-05	0.000192	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PGLS—osteoporosis	1.69e-05	0.000191	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GPD2—osteoporosis	1.69e-05	0.000191	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—ACP5—osteoporosis	1.67e-05	0.000189	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—osteoporosis	1.67e-05	0.000188	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—MYC—osteoporosis	1.63e-05	0.000184	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—TGFB1—osteoporosis	1.63e-05	0.000184	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—IL6—osteoporosis	1.56e-05	0.000177	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—TPI1—osteoporosis	1.56e-05	0.000176	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PNP—osteoporosis	1.54e-05	0.000174	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—ATIC—osteoporosis	1.54e-05	0.000174	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—IDH2—osteoporosis	1.53e-05	0.000173	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—P4HB—osteoporosis	1.46e-05	0.000165	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CYP27A1—osteoporosis	1.44e-05	0.000163	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—GAPDH—osteoporosis	1.44e-05	0.000162	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—osteoporosis	1.42e-05	0.00016	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—osteoporosis	1.41e-05	0.000159	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—ACP5—osteoporosis	1.4e-05	0.000158	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	1.38e-05	0.000156	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—NFATC1—osteoporosis	1.37e-05	0.000154	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—DKK1—osteoporosis	1.35e-05	0.000153	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—osteoporosis	1.32e-05	0.000149	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—OXCT1—osteoporosis	1.31e-05	0.000148	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CA2—osteoporosis	1.31e-05	0.000148	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—WNT1—osteoporosis	1.3e-05	0.000147	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—TPI1—osteoporosis	1.3e-05	0.000147	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—MGLL—osteoporosis	1.28e-05	0.000144	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—FGA—osteoporosis	1.27e-05	0.000143	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—IL6—osteoporosis	1.23e-05	0.000138	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—P4HB—osteoporosis	1.23e-05	0.000138	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—GAPDH—osteoporosis	1.2e-05	0.000136	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—RAP1A—osteoporosis	1.17e-05	0.000132	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—ENO1—osteoporosis	1.13e-05	0.000128	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PSMA2—osteoporosis	1.11e-05	0.000126	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PSMA5—osteoporosis	1.11e-05	0.000126	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—IDH2—osteoporosis	1.09e-05	0.000123	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CALCA—osteoporosis	1.04e-05	0.000117	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—POMC—osteoporosis	1.02e-05	0.000115	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CYP27A1—osteoporosis	1.02e-05	0.000115	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—osteoporosis	1e-05	0.000113	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—osteoporosis	1e-05	0.000113	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—ACP5—osteoporosis	9.94e-06	0.000112	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—ENO1—osteoporosis	9.48e-06	0.000107	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—KL—osteoporosis	9.43e-06	0.000107	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—ADCY5—osteoporosis	9.37e-06	0.000106	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—osteoporosis	9.34e-06	0.000106	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PSMA5—osteoporosis	9.34e-06	0.000105	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PSMA2—osteoporosis	9.34e-06	0.000105	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—TPI1—osteoporosis	9.24e-06	0.000104	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—P4HB—osteoporosis	8.69e-06	9.82e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GAPDH—osteoporosis	8.53e-06	9.63e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—RAP1A—osteoporosis	8.31e-06	9.38e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CYP19A1—osteoporosis	7.57e-06	8.55e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—ADCY5—osteoporosis	7.39e-06	8.35e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—MTHFR—osteoporosis	6.8e-06	7.68e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—ENO1—osteoporosis	6.72e-06	7.59e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PSMA2—osteoporosis	6.62e-06	7.47e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PSMA5—osteoporosis	6.62e-06	7.47e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—IRS2—osteoporosis	6.47e-06	7.3e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—ADCY5—osteoporosis	6.19e-06	6.99e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—GPX1—osteoporosis	6.17e-06	6.97e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—MTHFR—osteoporosis	5.69e-06	6.43e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—IRS1—osteoporosis	5.64e-06	6.37e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CYP19A1—osteoporosis	5.37e-06	6.06e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—IL6R—osteoporosis	5.3e-06	5.99e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—POMC—osteoporosis	4.55e-06	5.14e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—ADCY5—osteoporosis	4.39e-06	4.95e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GPX1—osteoporosis	4.37e-06	4.94e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—MTHFR—osteoporosis	4.04e-06	4.56e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—POMC—osteoporosis	3.23e-06	3.64e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—MYC—osteoporosis	3.14e-06	3.55e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—TGFB1—osteoporosis	3.13e-06	3.54e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—IL6—osteoporosis	2.36e-06	2.67e-05	CbGpPWpGaD
